Ibex Decision Support
Empower pathologists to make quicker and more accurate diagnosis with state-of-the-art decision-support tools
From the press
The Lancet Reports Outstanding Performance of Ibex Medical Analytics’ AI-based Algorithm in a Study at UPMC
Read More
From the press
New Milestone for Cancer Diagnostics in France as Ibex Medical Analytics Deploys its AI-Based Technology for Pathology at Medipath
Read More
From the press
UK’s First Rollout of AI-based Cancer Detection for NHS Patients as Pathology Provider LDPath Teams Up with Ibex Medical Analytics
Read More
From the press
Ibex CEO discusses how AI systems are expected to be more widely adopted and have a more active role in diagnostic processes in coming years.
Read More
From the press
Ibex’s Galen™ Prostate solution demonstrates outstanding results in a blinded study and supports pathologists in providing accurate diagnosis, enhanced lab efficiency and quality control
Read More
From the press
The Ibex Second Read™ System for breast is now deployed at Maccabi's pathology institute, making it the first lab in the world to implement AI-powered cancer diagnostics for breast biopsies in its routine clinical practice
Read More
From the press
Stuart Shand Joins Ibex Medical Analytics' management team as Chief Commercial Officer. Shand’s extensive experience in the digital pathology market will help grow the company’s business
Read More
From the press
Inspirata and IBEX Medical Analytics announce new technical partnership at the European Congress of Pathology (ECP) enabling joint customers to utilise artificial intelligence-based image analysis to reduce cancer case turnaround time and mitigate diagnostic errors.
Read More
From the press
Ibex Medical Analytics is among DigitalHealth.London's 20 new digital health care innovators. The prestigious accelerator has recently announced the innovators to be supported by the 2019-20 program at a launch event in central London.
Read More
From the press
Ibex Medical Analytics, a pioneer in Artificial Intelligence-based cancer diagnostics, and Medipath, the largest network of private pathology labs in France, announce today a partnership, designed to introduce artificial intelligence to the workflow in Medipath’s pathology labs and co-develop the next generation of Ibex’s product suite.
Read More
Ibex has been playing an important role in advancing AI-based technologies in pathology and is the first company to implement an AI-driven diagnostic system in routine clinical use. I am a huge advocate of the work of this company.
Sylvia L. Asa, MD, MPH
Former USCAP President and Chief Pathologist at UHN Toronto
I am deeply impressed with the Ibex Second Read system and with the performance of its algorithms, as well as with how quickly the Ibex team was able to deploy a system and integrate it into the routine clinical workflow of a large pathology institute. This disruptive technology is a game-changer.
Daniel Val Garijo, MD
Pathologist, Laboratoire National de Santé, Luxembourg
I’m extremely happy to be collaborating with Ibex on transforming cancer diagnostics – and thrilled to have deployed the Ibex Second Read system at Maccabi, rendering the Maccabi pathology institute the first in the world to deploy such a system in our routine workflow, and the first to demonstrate the value of AI in reversing a missed cancer diagnosis in real time.
Prof. Varda Shalev, MD, MPH
Managing Director, Morris Kahn & Maccabi Research and Innovation Institue at Maccabi Health care Services
The advent of digital pathology enables the implementation of AI-driven technologies to ensure more accurate and rapid cancer diagnosis in pathology institutes. We believe that systems such as the one developed by Ibex have an important role in advancing routine anatomic pathology practice. We will be assessing the performance of the Ibex Second Read system to determine its potential for implementation at UPMC.